{
  "id": 11518123,
  "title": "Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
  "url": "https://urgent.news/2026/10/02/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-02T20:03:42.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14"
  },
  "original_language": "en",
  "account": "Xenon Pharmaceuticals disclosed that it granted inducement stock options and restricted stock units to its employees. The share options were exercised at $38.93 per share, matching the closing price on the grant date of October 1, 2026. The options vest in stages over four years, with 25% of the shares becoming vested on the one-year anniversary of the employee's start date. The remaining options gradually vest monthly, subject to the employee's continued service with the company. Each option has a 10-year term and is bound by the terms of the share option agreement and the company's 2025 Inducement Equity Incentive Plan. Additionally, the company granted restricted stock units, which also vest over four years, with 25% of the shares becoming vested annually. The RSUs are also subject to the terms of the restricted share unit agreement and the 2025 Inducement Equity Incentive Plan.",
  "summary": "VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}